Navigation Links
Aflac Japan To Offer Cancer Insurance Product Through Japan Post
Date:11/16/2007

COLUMBUS, Ga., Nov. 16 /PRNewswire-FirstCall/ -- Aflac Incorporated announced today that Japan Post Network Co., Ltd., a subsidiary of Japan Post Holdings Co., Ltd., has selected Aflac Japan as the exclusive provider of cancer insurance for distribution through the nationwide postal office network.

Japan Post Network Co. is one of four separate postal entities that began operating in October 2007 as a part of the postal privatization process set forth under laws enacted in 2005. Japan Post Network Co. operates approximately 24,000 post office locations throughout Japan.

Commenting on the announcement, Aflac Incorporated Chairman and Chief Executive Officer Daniel P. Amos said: "We are very pleased that Japan Post chose our cancer insurance product for sale through its extensive network. We believe Japan Post's selection of Aflac reflects the quality of our newly introduced Cancer Forte product, the overall strength of the Aflac brand, a reputation for quality customer service and the support we provide to our sales force. Although Japan Post has not yet established a specific time frame for sales to commence, we anticipate that sales should occur sometime in 2008."

Amos added: "Throughout 2007, we have been encouraged by the overall direction of Aflac Japan's new annualized premium sales. We continue to believe that our sales will be flat to up 4% in the second half of 2007. And although we have not yet finalized our marketing plans and objectives for 2008, our preliminary expectation is that Aflac Japan's sales should increase 3% to 7% next year."

For more than 50 years, Aflac products have given policyholders the opportunity to direct cash where it is needed most when a life-interrupting medical event causes financial challenges. Aflac is the number one provider of guaranteed-renewable insurance in the United States and the number one insurance company in terms of individual insurance policies in force in Japan. Our insurance products provide protection to more than 40 million people worldwide. Aflac has been included in Fortune magazine's listing of America's Most Admired Companies for seven consecutive years and in Fortune magazine's list of the 100 Best Companies to Work For in America for nine consecutive years. Aflac has also been recognized three times by both Fortune magazine's listing of the Top 50 Employers for Minorities and Working Mother magazine's listing of the 100 Best Companies for Working Mothers. Aflac Incorporated is a Fortune 500 company listed on the New York Stock Exchange under the symbol AFL. To find out more about Aflac, visit aflac.com.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. We desire to take advantage of these provisions. This document contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC).

Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks, and uncertainties. In particular, statements containing words such as "expect," "anticipate," "believe," "goal," "objective," "may," "should," "estimate," "intends," "projects," "will," "assumes," "potential," "target," or similar words as well as specific projections of future results, generally qualify as forward-looking. Aflac undertakes no obligation to update such forward-looking statements.

We caution readers that the following factors, in addition to other factors mentioned from time to time could cause actual results to differ materially from those contemplated by the forward-looking statements: legislative and regulatory developments; assessments for insurance company insolvencies; competitive conditions in the United States and Japan; new product development and customer response to new products and new marketing initiatives; ability to attract and retain qualified sales associates and employees; ability to repatriate profits from Japan; changes in U.S. and/or Japanese tax laws or accounting requirements; credit and other risks associated with Aflac's investment activities; significant changes in investment yield rates; fluctuations in foreign currency exchange rates; deviations in actual experience from pricing and reserving assumptions including, but not limited to, morbidity, mortality, persistency, expenses, and investment yields; level and outcome of litigation; downgrades in the company's credit rating; changes in rating agency policies or practices; subsidiary's ability to pay dividends to parent company; ineffectiveness of hedging strategies; catastrophic events; and general economic conditions in the United States and Japan.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO )

Analyst and investor contact - Kenneth S. Janke Jr., 800.235.2667 - option 3, FAX: 706.324.6330, or kjanke@aflac.com.

Media contact - Laura Kane, 706.596.3493, FAX: 706.320.2288, or lkane@aflac.com.


'/>"/>
SOURCE Aflac Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Aflac Announces Resignation of U.S. Marketing Officer
2. Aflac Incorporated to Release Third Quarter Results On October 23, 2007
3. Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend
4. Aflac Honors Hispanic Entrepreneurs Making a Difference in Texas
5. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
6. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
7. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
8. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
9. Mannatech Hosts Japan National Convention
10. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
11. Abaxis Announces Appointment of New Distribution Partner in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... ... , ... Gout is like no other joint pain. It strikes suddenly, like ... swelling and redness. It is triggered by the crystallization of uric acid within the ... susceptible, according to the February 2016 issue of Harvard Men's Health Watch. , The ...
(Date:2/10/2016)... ... ... AHRA: The Association for Medical Imaging Management announced today ... as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead with ... with their own organizational staff and leadership. , “I am so excited ...
(Date:2/10/2016)... ... 10, 2016 , ... A national ergonomics pioneer , ... event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the expo ... longest running and largest worker's compensation event in Ohio, organizers of the safety ...
(Date:2/10/2016)... Middleboro, MA (PRWEB) , ... February 10, 2016 ... ... of their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns ... to provide a solution that ensures the integrity of biological samples while operating ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016 Antibacterial Drugs Market - ... - 2023 ", reveals that the global antibacterial drugs market ... to 2023 owing to patent expiries of blockbuster drugs. Even ... during the forecast period, the value is anticipated to decline ... --> Antibacterial Drugs Market - Global Industry Analysis, ...
(Date:2/10/2016)... 10, 2016  Silicon Biosystems Menarini Inc., a ... help uncover the biological complexities of disease at ... developer of innovative technologies for genomics research, today ... at enabling translational researchers to obtain high-quality sequencing ... tumor and normal cells in an optimized and ...
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
Breaking Medicine Technology: